Who We Are :
Cogent Biosciences is a publicly traded biotechnology company dedicated to developing precision therapies for genetically defined diseases. By leveraging validated biology and a rational drug discovery approach, Cogent aims to create real solutions that address the underlying drivers of disease and offer meaningful hope to patient's.
The company's lead therapeutic candidate, bezuclastinib, is a highly selective tyrosine kinase inhibitor designed to potently target KIT D816V and other mutations in KIT exon 17. These mutations are known drivers of systemic mastocytosis (SM) and advanced gastrointestinal stromal tumors (GIST) - both serious conditions driven by oncogenic KIT signaling. Bezuclastinib is currently being evaluated in multiple registration-directed trials across Non-Advanced SM (NonAdvSM), Advanced SM (AdvSM), and GIST. In July 2025, Cogent announced that its registration-direct SUMMIT trial in patients with NonAdvSM achieved statistical significance across all primary and key secondary endpoints, and the company is on track to file its first New Drug Application for this patient population by the end of 2025. The company also remains on track to announce top-line results for its APEX trial in patients with AdvSM in the second half of 2025 and for its PEAK trial in patients with GIST by the end of 2025. The company also has an ongoing Phase 1 study of its novel internally discovered FGFR2 inhibitor, and the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting other serious, genetically driven diseases targeting mutations in ErbB2, PI3Kα and KRAS.
Through its commitment to precision medicine and targeted innovation, Cogent Biosciences is working to transform the treatment landscape for patients with serious and underserved diseases. By leveraging validated biology and a rational drug discovery approach, Cogent aims to create real solutions that address the underlying drivers of disease. Our culture of inquisitiveness fuels continuous learning and innovation; we challenge assumptions, ask bold questions, and embrace a mindset of discovery to uncover transformative insights.
The Role :
This is an exciting opportunity to contribute to the growth of the Biometrics organization. The Senior Director, Statistical Programming provides expert support for statistical programming deliverables and milestones from study start-up through regulatory submission, working closely with internal teams and external vendors.
The ideal candidate is an experienced statistical programmer who can work independently, collaborate effectively across functions, and ensure programming activities are completed with high quality and efficiency. You will play a key role in driving process consistency, ensuring compliance, and supporting timely, high-quality data deliverables.
In this role, you will contribute to functional initiatives such as vendor coordination, systems integration, and process improvement. You will also assist in developing and maintaining SOPs and best practices to support high-quality programming deliverables and compliance with internal and external standards.
You will collaborate with study and program team members to implement project plans, ensure vendor activities meet expectations, and provide programming support for clinical trials. Responsibilities include developing study-level quality and oversight plans, tracking timelines and deliverables, and aligning programming activities with program goals.
Responsibilities :
Serve as a primary contact for statistical programming vendors; support coordination of programming deliverables, including :
Qualifications :
Constructing technical programming specifications
Salary Range :
$250,000 - 280,000 USD
Target Bonus : 25%
Exact compensation will vary based on skills, experience, and location.
Our Locations
Waltham, MA : Our Boston office includes an open office layout that has recently undergone a makeover designed for collaboration and giving our employees the best work place possible. Free access is provided for both on-site parking and gym facilities in the building.
Boulder, CO : We have just moved into our new state-of-the art Research Facility in the fast-growing biopharmaceutical hub in the greater Denver / Boulder corridor. Our CEO is based full-time in this location and we are proud to call this the home of Cogent's discovery research organization.
Our Offer To You
To attract the very best talent, we offer a generous benefits package that includes competitive pay, performance-based bonus, stock options, insurance coverage (health, dental, life, and disability), competitive time-off, a 401(k) plan, and commuter / parking benefits.
We are proud to be an Equal Opportunity Employer. Our goal is to have a diverse workforce. We do not discriminate on the basis of race, age, color, religion, national origin, gender, sexual orientation, gender identity or expression, veteran status or disability, or any other status protected under federal, state, or local law. All employment is decided on the basis of qualifications, merit, and business need.
Director Statistical Programming • Waltham, MA, United States